EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 173 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $515,364 | -8.9% | 32,680 | +12.3% | 0.00% | 0.0% |
Q2 2023 | $565,782 | -89.3% | 29,104 | -77.1% | 0.00% | -92.9% |
Q1 2021 | $5,310,000 | +7.9% | 127,206 | +20.4% | 0.01% | 0.0% |
Q4 2020 | $4,922,000 | +121.6% | 105,682 | +102.2% | 0.01% | +75.0% |
Q3 2020 | $2,221,000 | +33.2% | 52,273 | +50.4% | 0.01% | 0.0% |
Q2 2020 | $1,668,000 | -66.0% | 34,764 | -64.2% | 0.01% | -50.0% |
Q1 2019 | $4,900,000 | +30.4% | 97,049 | +4.1% | 0.02% | +6.7% |
Q4 2018 | $3,757,000 | +3.7% | 93,260 | +94.7% | 0.02% | +36.4% |
Q2 2018 | $3,624,000 | +36.6% | 47,901 | +43.3% | 0.01% | +10.0% |
Q4 2016 | $2,653,000 | +603.7% | 33,437 | +259.5% | 0.01% | +400.0% |
Q1 2016 | $377,000 | -76.7% | 9,300 | -49.0% | 0.00% | -75.0% |
Q4 2015 | $1,616,000 | -76.0% | 18,224 | -79.9% | 0.01% | -76.5% |
Q3 2015 | $6,727,000 | +96.6% | 90,870 | +114.7% | 0.03% | +112.5% |
Q2 2015 | $3,422,000 | +73.8% | 42,326 | -10.0% | 0.02% | +60.0% |
Q1 2015 | $1,969,000 | – | 47,005 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |